Inovio Pharmaceuticals Got Some Good News

By Jason Carr

In a report released today, Jason McCarthy from Maxim Group upgraded Inovio Pharmaceuticals (NASDAQ: INO) to Buy, with a price target of $10. The company’s shares closed yesterday at $6.87.

According to, McCarthy is ranked 0 out of 5 stars with an average return of -10.5% and a 36.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as ImmunoCellular Therapeutics, Mateon Therapeutics Inc, and Stellar Biotechnologies.

Inovio Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $11.

The company has a one year high of $11.69 and a one year low of $5.85. Currently, Inovio Pharmaceuticals has an average volume of 819.3K.

Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of INO in relation to earlier this year. Most recently, in January 2017, Niranjan Sardesai, the COO of INO bought 9,813 shares for a total of $60,056.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Inovio Pharmaceuticals, Inc. is a bio-pharmaceutical company, which develops active DNA immunotherapies for cancer and infectious diseases. Its portfolio of immune therapies includes SynCon immunotherapies and electroporation delivery systems. The company was founded on June 29, 1983 and is headquartered in Plymouth Meeting, PA.